|
Adenosine Therapeutics believes that adenosine receptor subtypes is where it's at. It develops and commercializes therapeutic compounds based on adenosine (an endogenous nucleoside) and its receptor subtypes. Adenosine Therapeutics is targeting drugs for treatment of conditions such as cardiac disease, diabetes, sickle cell anemia, and inflammatory disorders. The group's lead drug candidate is Stedivaze (apadenoson), a late-stage development drug for myocardial perfusion imaging. Adenosine Therapeutics was founded in 1999 and was acquired by Clinical Data in 2008.
|
| | | Contact Information | |
Address: |
Court Square Bldg., 310 4th St., Ste. 201
Charlottesville, VA 22905
| | Phone: | 434-220-9400 | | Fax: | 434-971-6912 |
|
|
Key People
| | • |
Chairman:
Jonathan M. Sackier
| | • |
CEO:
Robert S. Capon
| | • |
COO and CFO:
William B. Stilley
|
|
|
